30-day average of 11 articles Β· scale β100 to +100
Across 11 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Eli Lilly and Company news is Bullish (+54)
on a scale from β100 to +100.
That is down 6 points from the previous 30 days (+60).
π Eli Lilly stock surged 3% to a record high after China approved orforglipron (Foundayo).
π Foundayo approval positions Lilly ahead of Novo Nordisk for oral GLP-1 clearance in China.
Bullish +75
Eli Lilly (LLY) Stock Climbs as China Approves First GLP-1 Weight-Loss Pill
AI-generated analysis
Key insights
π Eli Lilly stock climbed nearly 3% to a record high after China approved orforglipron (Foundayo) as the nation's first GLP-1 weight-loss pill.
π Foundayo approval positions Lilly ahead of Novo Nordisk, which is still awaiting clearance for its oral Wegovy in China.
π The new oral therapy offers a once-daily, non-injection alternative that appeals to patients reluctant to use injections.
π J.P. Morgan forecasts China's GLP-1 weight-management market could reach $4.5 billion annually within five to seven years.
π¨π³ China's obese population is projected to top 65% by 2030, creating a massive growth opportunity for Foundayo.
π° Lilly reported strong third-quarter revenue of $24.4 billion, up 39%, driven by Mounjaro and Zepbound sales.
π Foundayo is already generating $184 million in Q3 revenue globally, with total lifetime revenue reaching $281 million since launch.
βοΈ Foundayo will compete against Lilly's own weekly injection as well as injectables from Novo Nordisk, Pfizer, and Innovent Biologics.
π More GLP-1 pill competitors are entering the Chinese market, including applications from Jiangsu Hengrui Pharmaceuticals and Huadong Medicine.
π Bullish signals
πEli Lilly stock hit a record high in premarket trading after China approved orforglipron (Foundayo) as the country's first GLP-1 weight-loss pill.
πFoundayo approval places Lilly ahead of competitor Novo Nordisk, which is still waiting for its oral Wegovy to be cleared in China.
πThe new oral therapy addresses patient preferences for non-injection treatments, potentially expanding the addressable market beyond current injectable users.
πAnalyst J.P. Morgan forecasts annual GLP-1 weight-management sales in China could reach $4.5 billion within five to seven years.
π¨China's obese population is projected to exceed 65% by 2030, providing a massive growth opportunity for Foundayo.
π°Lilly reported robust third-quarter revenue of $24.4 billion, a 39% increase driven by Mounjaro and Zepbound sales.
πFoundayo has generated $184 million in Q3 revenue globally, with total lifetime revenue reaching $281 million since its April FDA approval.
Article
Eli Lilly (LLY) shares surged nearly 3% in premarket trading after China's National Medical Products Administration approved orforglipron, sold as Foundayo, as the country's first GLP-1 weight-loss pill. This regulatory milestone establishes Lilly as a market leader ahead of competitor Novo Nordisk, whose oral Wegovy remains pending approval in China. The approval marks a significant expansion for Lilly into the world's second-largest pharmaceutical market with an oral therapy that addresses patient preferences for non-injection treatments.
Foundayo is designed to be taken once daily without food or water restrictions, offering a convenient alternative to injections and potentially expanding the addressable market beyond current injectable users. While Foundayo will compete with Lilly's own weekly GLP-1 injection as well as rival injectables from Novo Nordisk, Pfizer, and Innovent Biologics, the oral format is expected to capture significant demand given that oral therapies already account for roughly one-third of obesity prescriptions in the U.S.
Analyst J.P. Morgan forecasts that annual GLP-1 weight-management sales in China could reach 30 billion yuan ($4.5 billion) within five to seven years, driven by a growing obese population projected to exceed 65% by 2030. Lilly's broader financial performance remains robust, with total third-quarter revenue rising 39% to $24.4 billion, primarily driven by Mounjaro and Zepbound sales. The company has not yet disclosed specific pricing or launch timelines for Foundayo in China, though early availability on JD.com suggests imminent market entry.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Eli Lilly and Company (NYSE: LLY) has agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and milestone-based payments. The deal is expected to close in the fourth quarter of 2026 and aims to expand Lilly's immunology pipeline by accessing Merida's antibody-engineering platform designed to selectively eliminate disease-causing autoantibodies.
Merida's lead candidate, MER511, is currently in Phase 1 development for Graves' disease and thyroid eye disease (TED). Early data from the program showed substantial reductions in disease-related antibodies along with a favorable initial safety profile. This acquisition represents Lilly's broader strategy of using cash generated from its obesity and diabetes franchises to diversify into additional therapeutic areas.
The deal structure limits immediate risk as a portion of the purchase price depends on future development and commercial milestones rather than being paid entirely upfront. However, significant risks remain because MER511 is still in early-stage clinical development, and Lilly is paying a substantial premium for a young biotechnology company launched in 2025 that has raised only $121 million prior to the deal.
Competition is a concern as Graves' disease already has several treatment options, while TED has approved therapies including Amgen's Tepezza and Viridian Therapeutics' Lumvoa. While the acquisition strengthens Lilly's long-term growth prospects and reduces dependence on obesity and diabetes, it should be viewed as a long-term pipeline investment rather than an immediate earnings catalyst.
π LLY agrees to acquire Merida Biosciences for up to $2.875 billion.
π¬ Deal grants access to antibody platform targeting Graves' disease and TED.
β οΈ MER511 remains in Phase 1 with unproven patient improvement potential.
π° Acquisition uses cash from obesity/franchises to diversify into immunology.
π View as long-term pipeline investment rather than immediate earnings catalyst.
π Eli Lilly (LLY) agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash including upfront and milestone payments.
π¬ The acquisition grants Lilly access to Merida's antibody-engineering platform designed to selectively eliminate disease-causing autoantibodies while preserving normal immune function.
π Merida's lead candidate, MER511, is in Phase 1 development for Graves' disease and thyroid eye disease (TED) with early data showing substantial reductions in disease-related antibodies.
π‘οΈ The deal structure includes milestone-based payments to limit immediate financial risk as a portion of the purchase price depends on future development success.
β οΈ A major risk is that MER511 remains in Phase 1, meaning early antibody reductions do not guarantee meaningful patient improvements or success in larger clinical trials.
π° Lilly is paying up to $2.875 billion for a very young biotechnology company launched in 2025 that had raised only $121 million in Series A financing before the acquisition.
π₯ Competition is intense as Graves' disease has several existing treatment options and TED has approved therapies including Amgen's Tepezza and Viridian Therapeutics' Lumvoa.
π The deal strengthens Lilly's long-term growth prospects but should be viewed as a long-term pipeline investment rather than an immediate earnings catalyst.
π This acquisition fits Lilly's broader strategy of using cash from its obesity and diabetes franchises to diversify into additional therapeutic areas like immunology.
Bullish Signals
Acquiring Merida Biosciences for up to $2.875 billion to expand immunology pipeline.
Risk Factors
MER511 Phase 1 data may not predict trial success.
$2.875B premium paid for young firm with only $121M raised.
Competition from Amgen and Viridian threatens new therapy adoption.
Acquisition unlikely to impact near-term earnings.
Bullish Signals
Eli Lilly (LLY) is acquiring Merida Biosciences for up to $2.875 billion to expand its immunology pipeline and reduce reliance on its obesity and diabetes franchises.
The deal provides access to Merida's antibody-engineering platform designed to selectively eliminate disease-causing autoantibodies, offering a potentially differentiated treatment strategy.
Early Phase 1 data for MER511 showed substantial reductions in disease-related antibodies associated with Graves' disease and thyroid eye disease (TED) along with a favorable initial safety profile.
The acquisition structure includes milestone-based payments, meaning Lilly is not paying the entire $2.875 billion upfront but rather tying a portion of the cost to future development and commercial success.
Risk Factors
MER511 is still only in Phase 1 development, so early reductions in disease-causing antibodies do not guarantee that the treatment will produce meaningful improvements in patients or succeed in larger clinical trials.
Lilly is paying a substantial premium of up to $2.875 billion for a very young biotechnology company launched in 2025 that had raised only $121 million in Series A financing before the acquisition.
Competition is a significant concern as Graves' disease already has several treatment options and TED has approved therapies including Amgen's Tepezza and Viridian Therapeutics' Lumvoa, requiring Merida to demonstrate clear advantages.
The acquisition is unlikely to materially affect Lilly's near-term earnings as MER511 and other programs are at earlier stages with any major financial contribution likely several years away.
Eli Lilly and Co (LLY) shares opened down 3.57% on August 26, driven primarily by investor profit-taking following a multi-week surge toward record valuation levels. The stock underperformed the broader Pharmaceuticals & Medical Research sector as market participants rebalanced portfolios after a strong second-quarter performance that featured significant revenue growth and upwardly revised full-year guidance for key cardiometabolic therapies like Mounjaro and Zepbound.
Despite the intraday decline, analysts view the move as a healthy digestion of recent gains rather than a fundamental shift in the company's long-term commercial narrative. The article highlights that LLY maintains a formidable competitive moat within the cardiometabolic space, bolstered by next-generation pipeline candidates, upcoming oral formulation rollouts, and favorable long-term health outcome data. However, concerns persist regarding corporate and commercial health plan reimbursement dynamics for obesity treatments.
Specific headwinds include growing resistance from major employers opting out of covering GLP-1 medications to curb rising benefit expenditures, which could impact adoption volumes if coverage expansions face pushback. Additionally, the commercial rollout of the oral weight-loss drug Foundayo faces scrutiny over slower-than-expected initial adoption and elevated discontinuation rates relative to rival treatments. International expansion also faces headwinds from restrictive European reimbursement policies and public cost warnings from major regional health insurers.
π Shares opened down 3.57% on August 26 amid profit-taking after a multi-week surge.
π° Strong Q2 revenue and revised guidance driven by robust demand for Mounjaro and Zepbound.
π₯ Major employers opting out of GLP-1 coverage creates friction in commercial health plan adoption.
π Foundayo faces scrutiny over slower initial adoption and elevated discontinuation rates versus rivals.
π Analysts maintain Buy ratings with an average price target of $1,296.81.
π LLY shares opened down 3.57% on August 26 as investors engaged in profit-taking following the stock's multi-week surge toward record valuation levels.
π° The company reported strong second-quarter performance with significant revenue growth and upwardly revised full-year guidance driven by robust demand for Mounjaro and Zepbound.
π₯ Major employers are opting out of covering GLP-1 weight-loss medications to curb rising benefit expenditures, creating friction in commercial health plan adoption.
π The oral weight-loss drug Foundayo faces scrutiny over slower-than-expected initial adoption and elevated discontinuation rates compared to rival treatments.
πͺπΊ Restrictive European reimbursement policies and cost warnings from insurers like Germany's AOK present headwinds to international GLP-1 market expansion.
π Management disclosures revealed that Q2 outperformance was aided by non-recurring U.S. rebate adjustments, raising analyst concerns over potential growth deceleration in the second half of 2026.
π‘οΈ Eli Lilly maintains a strong competitive moat within the cardiometabolic space supported by next-generation pipeline candidates and favorable long-term health outcome data.
π Analysts maintain Buy ratings with an average price target of $1,296.81, though targets range widely from $850 to $1,600.
π Technical indicators show a neutral MACD signal and RSI at 47.992, while the Williams %R suggests a sell condition.
π LLY ranks 4th in annual revenue ($65.18B) and 2nd in net profit ($20.64B) within the Pharmaceuticals & Medical Research industry.
Bullish Signals
Strong cardiometabolic moat supported by next-gen pipeline.
Q2 revenue grew; full-year guidance raised on demand.
Risk Factors
Shares down 3.57% on profit-taking after record surge.
Employers cut obesity coverage to curb rising costs.
Foundayo faces scrutiny over slow adoption and high discontinuation.
European reimbursement policies hinder international GLP-1 expansion.
Q2 gains aided by non-recurring rebates, raising 2026 concerns.
Bullish Signals
Eli Lilly maintains a formidable competitive moat within the cardiometabolic space, bolstered by next-generation pipeline candidates and favorable long-term health outcome data.
The company achieved significant revenue growth in the second quarter with upwardly revised full-year guidance driven by robust demand for key therapies like Mounjaro and Zepbound.
Risk Factors
Shares opened down 3.57% as investors engaged in profit-taking following the stock's multi-week surge toward record valuation levels.
Growing concerns persist over corporate and commercial health plan reimbursement for obesity treatments, with major employers opting out of coverage to curb rising benefit expenditures.
The commercial rollout of oral weight-loss drug Foundayo faces scrutiny over slower-than-expected initial adoption and elevated discontinuation rates relative to rival treatments.
Restrictive European reimbursement policies and public cost warnings from major regional health insurers present headwinds to international GLP-1 market expansion.
Management disclosures revealed that Q2 outperformance was aided by non-recurring U.S. rebate adjustments, heightening analyst concerns over potential growth deceleration in the second half of 2026.
Eli Lilly (NYSE:LLY) raised its full-year revenue guidance following a quarter characterized by strong growth in its metabolic and obesity treatment portfolio. The company highlighted continued robust demand for its existing franchise, which has outpaced even elevated market expectations, driving the upward revision to its financial trajectory.
Significant positive momentum was generated by late-stage trial results for retatrutide, an experimental triple agonist designed to target multiple biological pathways simultaneously. These successful data readouts support a planned regulatory submission for this next-generation obesity treatment, reinforcing the durability of demand within Lilly's core therapeutic area and validating its pipeline strategy.
To meet surging demand that has consistently exceeded prior capacity planning, Eli Lilly committed substantial capital to expand manufacturing infrastructure, including new production facilities in Indiana. The company also closed several acquisitions during the quarter to bolster its pipeline across oncology, immunology, and other categories, while continuing to advance oral formulations and international regulatory approvals for its weight-loss treatments.
π Positive late-stage retatrutide trial results support planned regulatory submission.
π Committed capital to expand Indiana manufacturing capacity for surging demand.
π€ Closed multiple pipeline acquisitions and agreed to additional biotech deal.
π Received UK regulatory approval for weight-loss treatment, expanding internationally.
π Eli Lilly raised full-year revenue guidance driven by strong quarterly growth in its metabolic and obesity treatment portfolio.
π Late-stage trial results for the triple agonist retatrutide read out positively, supporting a planned regulatory submission for an obesity treatment.
π The company committed further capital to expand manufacturing capacity in Indiana to address surging demand for its flagship treatments.
π€ Eli Lilly closed several pipeline-focused acquisitions during the quarter while agreeing to acquire an additional biotechnology company post-quarter close.
π The company received regulatory approval for its weight-loss treatment in the United Kingdom, marking continued international expansion.
π° Management cited broad-based demand growth as the primary driver behind the raised revenue guidance trajectory range.
π¬ Retatrutide represents a next-generation candidate building on the success of Lilly's currently marketed metabolic treatments.
π The company is advancing oral formulations to offer non-injectable alternatives, broadening access for patients who prefer such options.
π‘οΈ Eli Lilly maintains a diversified portfolio spanning diabetes care, oncology, immunology, and neuroscience alongside its metabolic franchise.
π Market commentary highlighted the raised guidance as one of the more significant upward revisions among large pharmaceutical companies this year.
Bullish Signals
Eli Lilly raised full-year revenue guidance after posting strong quarterly growth across its metabolic and obesity treatment portfolio.
Positive late-stage trial results for retatrutide support a planned regulatory submission, reinforcing momentum in the company's core franchise.
The company closed several pipeline-focused acquisitions during the quarter to bolster assets in oncology, immunology, and other categories.
Eli Lilly received regulatory approval for its weight-loss treatment in the United Kingdom, expanding international access.
Management cited broad-based demand growth as the primary driver behind the raised revenue guidance trajectory range.
Eli Lilly (NYSE:LLY) raised its full-year revenue guidance following a quarter characterized by strong growth in its metabolic and obesity treatment portfolio. Management attributed this upward revision to sustained demand for existing treatments and positive late-stage trial results for retatrutide, an experimental triple agonist intended for regulatory submission as an obesity therapy.
The company is executing a significant capital expansion strategy to address supply constraints, including new manufacturing facilities in Indiana and partnerships with contract production organizations. These operational investments are designed to meet demand that has consistently outpaced prior capacity planning across its flagship metabolic franchise.
Beyond its core weight-loss drugs, Eli Lilly continues to diversify its pipeline through targeted acquisitions of smaller biotechnology firms in oncology, immunology, and neuroscience. The company also secured regulatory approval for its weight-loss treatment in the United Kingdom, reinforcing its international expansion while maintaining a broad therapeutic footprint.
Eli Lilly and Company (LLY) achieved a significant regulatory milestone with its weight-loss pill, Foundayo, receiving approval in the United Kingdom on August 10. This marks the first European country to clear the drug for both weight management and type 2 diabetes, positioning it as the second GLP-1 pill approved in Europe following Novo Nordisk's Wegovy. The UK launch is scheduled for later in the month via private prescriptions, with pricing set below Mounjaro's list price.
The article highlights a key competitive advantage for Foundayo: unlike Novo Nordisk's Wegovy, which requires taking on an empty stomach with a 30-minute wait before eating, Foundayo can be taken at any time without food or water restrictions. This convenience factor is central to Lilly's strategy to capture market share in the growing European obesity treatment sector.
Financially, Foundayo generated $98 million in US sales during the last quarter, contributing to an upward revision of LLY's 2026 revenue guidance to between $85 billion and $87 billion. However, adoption in the UK is expected to be slower than Wegovy's initial US performance due to the time required to build trust with prescribers and pending cost-effectiveness reviews by the NHS.
While Novo Nordisk maintains a substantial lead in European prescription volumes and recently reported strong second-quarter sales growth despite missing specific analyst expectations for Wegovy, LLY remains widely held by hedge funds. The rivalry has intensified, evidenced by Novo's lawsuit against Lilly regarding alleged deceptive advertising.
π¬π§ UK approved Foundayo as first dual-purpose weight loss and diabetes drug.
π° US sales hit $98M, raising LLY's 2026 guidance to $85-$87 billion.
βοΈ Novo Nordisk sued LLY over alleged deceptive advertising practices.
π UK adoption lags due to NHS reviews and need for brand trust.
π¦ Hedge fund ownership of LLY decreased slightly to 132 holders in Q1.
π¬π§ Eli Lilly's Foundayo received UK approval on August 10 as the first European drug cleared for both weight management and type 2 diabetes.
π½οΈ Foundayo offers a distinct convenience advantage over Novo Nordisk's Wegovy by allowing administration without food or water restrictions.
π° The new drug generated $98 million in US sales last quarter, prompting LLY to raise its 2026 revenue guidance to $85-$87 billion.
π UK adoption is expected to be slower than Wegovy's initial US launch due to pending NHS cost-effectiveness reviews and the need to build brand trust.
βοΈ Novo Nordisk maintains a significant head start in European markets with over 5 million total prescriptions for Wegovy since its January launch.
π Novo Nordisk shares dropped nearly 6% after reporting Q2 sales that missed analyst expectations and citing tougher US competition.
βοΈ The competitive rivalry has escalated, with Novo Nordisk filing a lawsuit against Eli Lilly over alleged deceptive advertising practices.
π¦ Hedge fund ownership of LLY decreased slightly to 132 holders in Q1 2026, though it remains more widely held than Novo Nordisk.
Bullish Signals
Foundayo won approval in the UK as the first European drug cleared for both weight management and type 2 diabetes.
The new pill offers a unique convenience edge by allowing patients to take it at any time without food or water restrictions, unlike competitors requiring empty stomachs.
Foundayo brought in $98 million in US sales last quarter, driving an upward revision of 2026 revenue guidance to $85 billion to $87 billion.
The drug is priced below Mounjaro's roughly Β£330 monthly list price for the upcoming UK private prescription launch.
Risk Factors
Adoption of Foundayo in the US has been slower than Wegovy, reflecting the time needed to build trust with doctors and patients.
NHS access in the UK is not automatic and depends on a pending cost-effectiveness review, limiting early patient access to private payers.
The drug remains under review by the European Union while competitor Wegovy has already secured a positive recommendation there.
Novo Nordisk has sued Eli Lilly over allegedly deceptive advertising, highlighting intense competitive friction in the weight-loss market.
Eli Lilly (LLY) reported a robust second quarter with revenue surging 48% year-over-year, driven primarily by its GLP-1 weight loss portfolio. The company received a significant regulatory milestone on August 10 when the UK's Medicines and Healthcare products Regulatory Agency approved Foundayo, an oral GLP-1 for weight management and type 2 diabetes. This approval made Britain the first European market to greenlight the pill, causing LLY stock to rise nearly 4%. The company is now under regulatory review in over 40 additional countries, with a global rollout expected across major markets by 2027.
Lilly is strategically diversifying its treatment portfolio beyond injectables like Zepbound by adding oral options and developing retatrutide for patients requiring deeper weight loss or managing complications like sleep apnea. Management highlighted that more than 80% of Foundayo prescriptions went to patients who had never taken a GLP-1 before, indicating market expansion rather than cannibalization of existing sales. Consequently, the company raised its full-year revenue guidance to between $85 billion and $87 billion, reflecting strong demand and successful access programs like the new Medicare initiative.
Despite the growth, the article notes significant valuation concerns and competitive headwinds. LLY trades at 32.47 times forward earnings, well above the healthcare sector average of 18.5x, assuming continued compounding growth without stumbles. The portfolio remains concentrated with Mounjaro and Zepbound accounting for 65% of second-quarter revenue. Additionally, average realized prices across the GLP-1 portfolio fell 13% year-over-year due to price cuts aimed at widening access, though volume increased by 60%. Competition is intensifying as Novo Nordisk's CagriSema approaches and patent protections for semaglutide expire in key markets like India, China, and Brazil.
The article concludes that while LLY has successfully transformed a single drug into a multi-product platform with expanding regulatory reach, the high valuation leaves little cushion against potential volume erosion from rivals or generic competition. Hedge fund ownership saw a modest decline to 132 funds, yet short interest remains low at 1.02% of the float. The core investment thesis rests on whether the company can maintain its growth trajectory despite these concentration risks and pricing pressures.
π Q2 revenue surged 48% with adjusted EPS of $8.38.
π¬π§ UK MHRA approved Foundayo, the first European oral GLP-1.
π Foundayo requires no fasting, unlike Novo Nordisk's Wegovy.
π Portfolio prices fell 13%, but volume jumped 60%.
β οΈ Mounjaro and Zepbound drove 65% of second-quarter revenue.
π Eli Lilly reported a 48% year-over-year revenue increase in Q2, with adjusted EPS reaching $8.38.
π¬π§ The UK MHRA approved Foundayo, an oral GLP-1, making it the first European market to greenlight the pill.
π Foundayo is currently under regulatory review in over 40 additional countries with a global rollout expected by 2027.
π Foundayo offers a distinct advantage over Novo Nordisk's oral Wegovy as it does not require patients to fast for 30 minutes before ingestion.
π Management raised full-year revenue guidance to a range of $85 billion to $87 billion.
π₯ More than 80% of Foundayo prescriptions were issued to patients who had never previously taken a GLP-1 drug.
π° Average realized prices across the GLP-1 portfolio fell 13% year-over-year due to strategic price cuts to widen access.
π Volume for the GLP-1 portfolio increased by 60% over the same period, offsetting the decline in average prices.
β οΈ Mounjaro and Zepbound combined accounted for 65% of second-quarter revenue, highlighting portfolio concentration risk.
π LLY trades at 32.47 times forward earnings, significantly higher than the 18.5x average for healthcare stocks.
βοΈ Competition is intensifying with Novo Nordisk's CagriSema approaching and semaglutide patents expiring in India, China, and Brazil.
π Hedge fund ownership of Eli Lilly decreased from 137 funds to 132 in the most recent quarter.
Bullish Signals
48% year-over-year revenue growth in Q2.
UK approval expands geographic footprint.
Raised full-year guidance to $85-$87 billion.
Captures needle-averse patients without cannibalization.
80% prescriptions from first-time GLP-1 users.
60% volume growth offset 13% price decline.
Risk Factors
Valuation at 32.47x earnings vs 18.5x sector average.
Mounjaro and Zepbound comprise 65% of Q2 revenue.
Realized prices fell 13% year-over-year due to cuts.
Patent expirations in India, China, Brazil invite generics.
Hedge fund ownership dropped from 137 to 132.
Bullish Signals
LLY achieved a 48% year-over-year revenue growth in Q2, demonstrating strong commercial performance.
The UK regulatory approval for Foundayo expands the company's geographic footprint and product accessibility.
Management raised full-year revenue guidance to $85-$87 billion, signaling confidence in future demand.
Foundayo captures a new segment of needle-averse patients without cannibalizing existing injectable sales.
The company successfully expanded its market by securing over 80% of Foundayo prescriptions from first-time GLP-1 users.
Volume growth of 60% effectively offset the 13% decline in average realized prices, maintaining revenue momentum.
Risk Factors
LLY trades at a premium valuation of 32.47x forward earnings compared to the 18.5x sector average.
The portfolio is heavily concentrated with Mounjaro and Zepbound representing 65% of Q2 revenue.
Average realized prices fell 13% year-over-year due to price cuts intended to improve patient access.
Patent expirations for semaglutide in India, China, and Brazil open the door for generic competition.
Hedge fund ownership slipped from 137 to 132 funds, indicating some institutional caution.
The article contrasts Pfizer (PFE) and Eli Lilly (LLY) as divergent investment plays within the pharmaceutical sector. Pfizer is characterized as a value and income opportunity, trading at approximately 8.7x trailing adjusted earnings with a dividend yield of roughly 7%. Conversely, Eli Lilly is positioned as a growth stock driven by its dominant market share in obesity and diabetes franchises, evidenced by a 56% revenue jump in the first quarter.
Pfizer faces significant headwinds including a projected $1.5 billion decline in COVID-19 product revenue for 2026 and potential losses from generic competition on key drugs like Eliquis and Ibrance. The company is attempting to pivot into the obesity market via acquisitions but enters a space dominated by Eli Lilly and Novo Nordisk. Its investment thesis relies on substantial cash generation and a robust drug portfolio despite these normalization pressures.
Eli Lilly's growth strategy involves heavy investment in manufacturing capacity to meet demand for blockbuster drugs like Mounjaro and Zepbound, though this spending may weigh on near-term free cash flow. The stock trades at a premium valuation of roughly 40.7x trailing earnings, reflecting high expectations for continued expansion. Primary risks include intense pricing pressure, competition eroding margins, and the long-term threat of patent exclusivity loss on its core revenue drivers.
Hedge fund positioning data reveals that while Lilly holds strong institutional support with increased stakes from major firms like AQR Capital Management, Pfizer has seen significant interest increases from funds like Unisphere Establishment. The article concludes that while Pfizer offers a compelling value proposition with high dividends, Eli Lilly provides superior growth potential, though the author ultimately pivots to promoting AI stocks for higher returns.
π Pfizer trades at 8.7x earnings with a 7% dividend yield.
π Eli Lilly revenue surged 56% in Q1 driven by weight-loss drugs.
A comprehensive forensic report by BestBrokers reveals that Eli Lilly, the manufacturer of Mounjaro, generates approximately $1 million in profit every 25 minutes. The analysis covers the top 200 public companies by market capitalization and highlights Eli Lilly's exceptional financial performance over the last 12 months.
Eli Lilly recorded a net profit per employee of $412,264 in 2025, ranking second among 16 major pharmaceutical companies for the speed of profit generation. The report notes that Eli Lilly has surpassed Novo Nordisk to become the leading weight-loss drug manufacturer globally.
The top five earners in the studyβJohnson & Johnson, Eli Lilly, Merck, Roche, and Novo Nordiskβcollectively generated over $99 billion in net profit recently. Alan Goldberg of BestBrokers attributes this success to transformative trends like weight-loss drugs and AI in medicine, positioning these firms as key players reshaping global healthcare.
π Eli Lilly earns $1M profit every 25 minutes.
π° Lilly achieved $412,264 net profit per employee in 2025.
π Eli Lilly surpassed Novo Nordisk as top weight-loss drug maker.
π Johnson & Johnson leads with $1M profit every 19 minutes.
π Top five pharma firms generated over $99 billion last year.
π Eli Lilly generates approximately $1 million in profit every 25 minutes according to a new BestBrokers report.
π° The company achieved a net profit per employee of $412,264 in 2025.
π Eli Lilly has overtaken Novo Nordisk as the leading global weight-loss drug manufacturer.
π Johnson & Johnson ranks first with a profit generation rate of $1 million every 19 minutes.
π The top five pharma companies collectively generated over $99 billion in net profit over the last 12 months.
πΊπΈ Ten of the 16 analyzed pharmaceutical companies are based in the United States.
π¬ BestBrokers analysts highlight the industry's shift toward AI and next-generation therapies as key growth drivers.
Bullish Signals
Generates $1M profit every 25 minutes.
$412,264 net profit per employee in 2025.
Overtaken Novo Nordisk as global weight-loss leader.
Top five pharma firms generated over $99B.
Bullish Signals
Eli Lilly is generating $1 million in profit every 25 minutes, demonstrating extraordinary earning power.
The company achieved a net profit per employee of $412,264 in 2025, ranking second among major pharma firms for profit speed.
Eli Lilly has successfully overtaken Novo Nordisk to become the leading weight-loss drug manufacturer globally.
The top five pharmaceutical companies analyzed collectively generated more than $99 billion in net profit recently.
Amova Asset Management Americas Inc. established a new position in Eli Lilly and Company (NYSE:LLY) during the first quarter, purchasing 7,884 shares valued at approximately $7.25 million. Several other institutional investors, including Maryland Capital Advisors, Osbon Capital Management, Basso Capital Management, Maseco LLP, and E Fund Management Hong Kong Co. Ltd., also initiated or increased their stakes in the fourth quarter, with holdings ranging from roughly $25,000 to $31,000.
Wall Street analysts have recently issued mixed but generally positive ratings on Eli Lilly stock. Cantor Fitzgerald raised its target price to $1,350 with an overweight rating, while Truist Financial and Guggenheim lifted their price objectives to $1,370 and $1,273 respectively, both maintaining buy ratings. Goldman Sachs reaffirmed a buy rating at $1,283, though Wall Street Zen downgraded the stock from strong-buy to buy. The consensus target price stands at $1,283.64 with an average rating of Moderate Buy.
Financially, Eli Lilly reported strong quarterly results ending April 30th, beating earnings estimates significantly with $8.55 EPS compared to a consensus of $6.97. Revenue reached $19.80 billion, surpassing analyst expectations of $17.82 billion and representing a 55.5% year-over-year increase. The company maintains a robust balance sheet with a market cap of $1.08 trillion, a PEG ratio of 1.48, and has set full-year 2026 EPS guidance between $35.50 and $37.00.
The company recently announced a quarterly dividend of $1.73 per share, payable on September 10th to shareholders of record on August 14th, resulting in an annualized dividend yield of 0.6%. Currently trading around $1,146.90, the stock sits above its 50-day and 200-day moving averages. With a debt-to-equity ratio of 1.26 and a return on equity of 105.77%, Eli Lilly continues to demonstrate strong operational performance and financial health.
π Amova bought 7,884 shares worth $7.25 million in Q1.
π° EPS hit $8.55, beating estimates by $1.58 in Q2.
π Revenue reached $19.80 billion, up 55.5% year-over-year.
π― Full-year 2026 EPS guidance set between $35.50 and $37.00.
π΅ Quarterly dividend of $1.73 announced with ex-date Aug 14.
π Amova Asset Management Americas Inc. purchased a new position of 7,884 shares in Eli Lilly valued at approximately $7.25 million in the first quarter.
π¦ Multiple institutional investors including Maryland Capital Advisors and Maseco LLP initiated or increased stakes in the fourth quarter, with Maseco growing holdings by 466.7%.
π Cantor Fitzgerald raised its target price to $1,350 with an overweight rating, while Truist Financial lifted its objective to $1,370 with a buy rating.
π° Eli Lilly reported quarterly EPS of $8.55, beating the consensus estimate of $6.97 by $1.58 in the quarter ended April 30th.
π Revenue reached $19.80 billion, exceeding analyst estimates of $17.82 billion and growing 55.5% compared to the same quarter last year.
π― The company set full-year 2026 EPS guidance between $35.50 and $37.00, slightly above the consensus expectation of $34.55.
π΅ A quarterly dividend of $1.73 was announced with an ex-dividend date of August 14th and a payment date of September 10th.
π The stock trades at a PEG ratio of 1.48 with a market capitalization of $1.08 trillion and a price-to-earnings ratio of 40.74.
π Wall Street Zen downgraded the stock from strong-buy to buy, though the consensus rating remains Moderate Buy with a target of $1,283.64.
π’ Hedge funds and other institutional investors collectively own 82.53% of the company's outstanding stock.
Bullish Signals
EPS beat: $8.55 vs $6.97 estimate.
Revenue hit $19.8B vs $17.82B target.
YoY revenue surged 55.5%.
Cantor Fitzgerald raised target to $1,350.
Truist Financial set objective at $1,370.
Guggenheim lifted target to $1,273.
ROE stands at 105.77%.
2026 EPS guidance: $35.50-$37.00.
Risk Factors
Zen downgraded from strong-buy to buy.
Low 0.6% dividend yield limits income appeal.
Bullish Signals
Eli Lilly significantly beat quarterly earnings estimates with EPS of $8.55 versus a consensus of $6.97, demonstrating strong profitability.
Revenue of $19.80 billion exceeded analyst expectations of $17.82 billion, highlighting robust demand for the company's products.
Year-over-year revenue growth of 55.5% indicates sustained business expansion and market share gains.
Cantor Fitzgerald raised its price target to $1,350 with an overweight rating, signaling strong analyst confidence in future performance.
Truist Financial increased its price objective to $1,370 while maintaining a buy rating, reinforcing positive sentiment among major banks.
Guggenheim lifted its price target to $1,273 and reaffirmed a buy rating, contributing to the consensus Moderate Buy status.
The company maintains a high return on equity of 105.77%, reflecting efficient capital utilization and strong operational leverage.
Full-year 2026 EPS guidance of $35.50-$37.00 exceeds analyst consensus of $34.55, indicating management's confidence in future growth.
Risk Factors
Wall Street Zen downgraded the stock from strong-buy to buy, reflecting some caution among analysts despite recent positive earnings.
The dividend yield is relatively low at 0.6%, which may limit appeal for income-focused investors compared to other sectors.
Dorsey Wright & Associates increased its stake in Eli Lilly and Company (NYSE: LLY) by purchasing 508 shares valued at approximately $468,000 during the first quarter. Other institutional investors also adjusted their holdings, with Brighton Jones LLC increasing its position by 22.0% to own 9,597 shares worth $7.4 million, and Revolve Wealth Partners LLC adding 40 shares. Schnieders Capital Management LLC increased its stake by 16.7%, while Flow Traders U.S. LLC and Nebula Research & Development LLC acquired new stakes valued at roughly $356,000 and $749,000 respectively in the second quarter.
Major brokerages have recently upgraded their outlook for Eli Lilly, citing strong performance. Berenberg Bank raised its price target from $1,050 to $1,135 with a 'hold' rating, while Wolfe Research maintained an 'outperform' rating with a $1,350 target. UBS Group increased its target to $1,425 with a 'buy' rating, and Citigroup raised its target to $1,600. Royal Bank of Canada also boosted its target to $1,500 with an 'outperform' rating. Collectively, analysts hold 28 'Buy' or 'Strong Buy' ratings against just one 'Sell', reflecting a consensus average target price of $1,283.64.
Eli Lilly reported robust financial results for the quarter ended April 30, beating earnings estimates significantly. The company posted $8.55 EPS compared to the consensus of $6.97, driven by revenue of $19.80 billion which represented a 55.5% year-over-year increase. Key metrics included a net margin of 34.98% and a return on equity of 105.77%. The firm has set full-year 2026 guidance between $35.50 and $37.00 EPS, while the current quarter's consensus estimate stands at $34.55.
The stock currently trades with a market capitalization of $1.11 trillion and a P/E ratio of 41.85. Technical indicators show the stock trading above its 50-day moving average of $1,118.87 and its 200-day moving average of $1,036.80. The company recently announced a quarterly dividend of $1.73 per share, payable on September 10th to shareholders of record on August 14th, representing an annualized yield of 0.6% and a payout ratio of 24.58%.
π Dorsey Wright bought 508 shares for $468,000 in Q1.
π Brighton Jones increased holdings by 22% to 9,597 shares.
π° Flow Traders and Nebula Research acquired stakes worth $356k-$749k.
π¦ UBS raised target price to $1,425 with a 'buy' rating.
πΉ Eli Lilly reported $8.55 EPS, beating estimates by $1.58.
π Dorsey Wright & Associates purchased a new stake of 508 shares valued at $468,000 in the first quarter.
π Brighton Jones LLC increased its position by 22.0% to own 9,597 shares worth $7.4 million in the fourth quarter.
π Revolve Wealth Partners LLC and Schnieders Capital Management LLC also increased their stakes by 2.8% and 16.7% respectively.
π° Flow Traders U.S. LLC and Nebula Research & Development LLC acquired new stakes valued at approximately $356,000 and $749,000 in the second quarter.
π¦ Berenberg Bank raised its price target from $1,050 to $1,135 with a 'hold' rating on June 22nd.
π Wolfe Research reiterated an 'outperform' rating and issued a $1,350 target price on May 21st.
π UBS Group boosted its target price from $1,250 to $1,425 with a 'buy' rating on July 13th.
π΅ Citigroup upped its price target from $1,500 to $1,600 and maintained a 'buy' rating.
π¨π¦ Royal Bank of Canada raised its target from $1,250 to $1,500 with an 'outperform' rating on July 8th.
π Analyst consensus shows 28 Buy/Strong Buy ratings versus one Sell rating with an average target of $1,283.64.
πΉ Eli Lilly reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58.
π Revenue reached $19.80 billion, a 55.5% increase year-over-year against estimates of $17.82 billion.
π° The company achieved a net margin of 34.98% and a return on equity of 105.77%.
π Full-year 2026 guidance is set between $35.50 and $37.00 EPS, above analyst expectations of $34.55.
πΈ A quarterly dividend of $1.73 per share will be paid on September 10th to shareholders of record on August 14th.
π The stock trades at a P/E ratio of 41.85 with a market cap of $1.11 trillion.
π Technical analysis shows the stock trading above its 50-day moving average of $1,118.87 and 200-day average of $1,036.80.
π The company operates globally with a presence in North America, Europe, Asia, and emerging markets.
π€ CEO David A. leads the global pharmaceutical company founded in 1876 and headquartered in Indianapolis.
π Hedge funds and institutional investors collectively own 82.53% of the company's outstanding stock.
Bullish Signals
EPS beat: $8.55 vs $6.97 consensus.
Revenue surged 55.5% to $19.8B.
Net margin hit 34.98%; ROE at 105.77%.
Major banks raised targets with Buy ratings.
28 Buy vs 1 Sell analyst rating.
Stock trades above 50-day and 200-day moving averages.
Eli Lilly significantly beat quarterly earnings estimates, reporting $8.55 EPS versus a consensus of $6.97.
Revenue surged 55.5% year-over-year to $19.80 billion, exceeding analyst expectations of $17.82 billion.
The company demonstrated exceptional profitability with a net margin of 34.98% and a return on equity of 105.77%.
Multiple major brokerages including UBS Group, Citigroup, and Royal Bank of Canada raised their price targets and maintained 'buy' or 'outperform' ratings.
Analyst consensus is overwhelmingly positive with 28 Buy/Strong Buy ratings against only one Sell rating.
The stock trades above both its 50-day and 200-day moving averages, indicating strong technical momentum.
Institutional investors are actively accumulating shares, with Dorsey Wright & Associates, Brighton Jones LLC, and others increasing or initiating positions.
The company has set robust full-year 2026 guidance of $35.50-$37.00 EPS, which exceeds current analyst expectations of $34.55.
Institutional investor Atlas Wealth LLC purchased a new stake of approximately $1.225 million in Eli Lilly and Company (LLY) during the first quarter, adding 1,332 shares to its portfolio. Other notable institutional holders recently adjusted their positions, with Brighton Jones LLC increasing its stake by 22% in the fourth quarter and Revolve Wealth Partners raising holdings by 2.8%. Additionally, Schnieders Capital Management lifted its position by 16.7% in the second quarter, while Flow Traders U.S. LLC and Nebula Research & Development LLC established new stakes valued at roughly $356,000 and $749,000 respectively.
The article details current market metrics for LLY, noting a stock price opening at $1,178.01 with a market capitalization of $1.11 trillion. Key financial ratios include a P/E ratio of 41.85 and a price-to-earnings-growth ratio of 1.47. The company maintains a beta of 0.51, with a quick ratio of 1.10 and a current ratio of 1.50. LLY recently announced a quarterly dividend of $1.73 per share payable on September 10th to shareholders of record on August 14th, representing an annualized yield of 0.6%.
Wall Street analysts have issued mixed but generally positive ratings for the stock following recent reports. Barclays raised its price target from $1,350 to $1,400 with an overweight rating, while Guggenheim and Truist Financial increased their targets to $1,273 and $1,370 respectively, both maintaining buy ratings. Sanford C. Bernstein also upgraded its target to $1,385 with an outperform rating. The consensus rating remains Moderate Buy with an average price target of $1,283.64.
π Atlas Wealth acquired $1.225M Eli Lilly position in Q1.
π Brighton Jones increased stake 22% to $7.409M value.
π° Flow Traders and Nebula established new stakes totaling $1.1M.
π΅ Quarterly dividend of $1.73 payable Sept 10th to record holders.
π Consensus rating is Moderate Buy with $1,283.64 target price.
π Atlas Wealth LLC acquired a new position in Eli Lilly valued at approximately $1.225 million during the first quarter.
π Brighton Jones LLC increased its stake by 22% in the fourth quarter, now holding shares worth $7.409 million.
π Revolve Wealth Partners raised its holdings by 2.8% in the fourth quarter, adding 40 shares to its portfolio.
π Schnieders Capital Management lifted its stake by 16.7% in the second quarter, purchasing an additional 1,141 shares.
π° Flow Traders U.S. LLC and Nebula Research & Development LLC established new stakes valued at $356,000 and $749,000 respectively.
π LLY stock opened at $1,178.01 with a market capitalization of $1.11 trillion and a P/E ratio of 41.85.
π΅ The company announced a quarterly dividend of $1.73 per share payable on September 10th to shareholders of record on August 14th.
π Barclays raised its price target from $1,350 to $1,400 and maintained an overweight rating in a recent report.
π Wall Street Zen downgraded the stock from a strong-buy rating to a buy rating in a research report.
π Guggenheim boosted its target price to $1,273 and reaffirmed a buy rating in a July 13th note.
π Truist Financial raised its price target to $1,370 with a buy rating following a July 8th analysis.
π Sanford C. Bernstein increased its target price to $1,385 and assigned an outperform rating recently.
π The consensus analyst rating is Moderate Buy with an average price target of $1,283.64 based on MarketBeat data.
Bullish Signals
Atlas Wealth initiated $1.225M position in Q1.
Brighton Jones increased stake by 22% in Q4.
Schnieders Capital raised holdings by 16.7% in Q2.
Barclays upgraded target to $1,400 with overweight rating.
Guggenheim raised target to $1,273 with buy rating.
Risk Factors
Wall Street Zen downgraded stock from strong-buy to buy.
One analyst assigned sell rating vs consensus moderate buy.
Average target $1,283.64 slightly below recent opening price.
Bullish Signals
Atlas Wealth LLC initiated a new position in Eli Lilly valued at approximately $1.225 million during the first quarter.
Brighton Jones LLC significantly increased its stake by 22% in the fourth quarter, demonstrating strong institutional confidence.
Schnieders Capital Management raised its holdings by 16.7% in the second quarter, adding over $6 million to its position.
Barclays upgraded its price target from $1,350 to $1,400 and maintained an overweight rating on the stock.
Guggenheim increased its price target to $1,273 while reaffirming a buy rating in a recent research note.
Truist Financial raised its price target to $1,370 and assigned a buy rating following a July 8th analysis.
Sanford C. Bernstein boosted its target price to $1,385 with an outperform rating in a Tuesday report.
The company maintains a strong balance sheet with a quick ratio of 1.10 and a current ratio of 1.50.
Risk Factors
Wall Street Zen downgraded the stock from a strong-buy rating to a buy rating, indicating some caution among analysts.
One analyst has assigned a sell rating to the stock, contributing to a consensus Moderate Buy rather than Strong Buy.
The average analyst price target of $1,283.64 is slightly below the recent opening price of $1,178.01, suggesting mixed near-term expectations.
Eli Lilly (LLY) shares dipped slightly to $1,155.52 after announcing a strategic acquisition of AtaiBeckley for an upfront payment of $2.8 billion. The deal aims to significantly bolster Lilly's neuroscience division by integrating advanced-stage depression treatments into its existing portfolio, specifically targeting treatment-resistant depression.
The transaction includes contingent value rights that could push the total valuation up to approximately $3.8 billion, contingent on achieving specific clinical and regulatory milestones. The acquisition is projected to close in the third quarter of 2026, following shareholder approval and standard regulatory clearances.
AtaiBeckley's flagship asset, BPL-003, an intranasal synthetic derivative of 5-MeO-DMT, has secured FDA Breakthrough Therapy designation. Phase 2b data showed swift improvements in depression severity with effects lasting months, and the candidate is now advancing into Phase 3 trials.
A secondary asset, VLS-01, utilizes a buccal film delivery system containing DMT and is currently in an active Phase 2b trial. Both compounds work by restoring synaptic connections rather than modulating neurotransmitters, representing a novel mechanism of action for mental health disorders.
π LLY shares dipped 0.1% after announcing $2.8B AtaiBeckley acquisition.
π° Deal value could reach $3.8B with contingent milestones.
π Transaction expected to close in Q3 2026.
π§ BPL-003 holds FDA Breakthrough Therapy status for depression.
βοΈ Both assets restore synaptic connections via novel mechanisms.
π LLY shares declined 0.10% to $1,155.52 following the announcement of the $2.8 billion acquisition of AtaiBeckley.
π° The deal includes contingent value rights that could increase the total transaction value to approximately $3.8 billion upon meeting milestones.
π The acquisition is projected to finalize during the third quarter of 2026 pending shareholder and regulatory approvals.
π§ AtaiBeckley's flagship asset BPL-003 has received FDA Breakthrough Therapy designation for treatment-resistant depression.
π¬ Phase 2b clinical data for BPL-003 demonstrated swift and sustained improvements in depression severity during brief clinic visits.
π The lead candidate is an intranasal synthetic derivative of 5-MeO-DMT designed to restore synaptic connections.
π A secondary asset, VLS-01, employs a buccal film delivery system containing DMT and is progressing through Phase 2b trials.
βοΈ Both therapeutic candidates utilize a novel mechanism of action focused on synaptic restoration rather than neurotransmitter modulation.
π€ The Board of Directors for both organizations has granted approval for the transaction prior to the public announcement.
π¦ Goldman Sachs served as Lilly's financial advisor, while Moelis & Company and others provided legal and financial support.
Bullish Signals
FDA Breakthrough Therapy designation for BPL-003.
Phase 2b data shows sustained depression improvements.
Acquisition strengthens neuroscience capabilities and pipeline.
Advanced-stage treatments reduce early discovery risk.
VLS-01 progresses through active Phase 2b trial.
Risk Factors
Stock declined 0.10% near daily low.
$1.0 billion contingent on uncertain outcomes.
Deal finalizes Q3 2026 with long timeline.
Bullish Signals
The acquisition significantly strengthens Eli Lilly's neuroscience capabilities and broadens its therapeutic options for treatment-resistant depression.
BPL-003 has secured FDA Breakthrough Therapy designation, indicating high potential for accelerated development and regulatory approval.
Phase 2b clinical data demonstrated the ability to deliver swift and sustained improvements in depression severity with effects persisting for multiple months.
The deal incorporates advanced-stage depression treatments into Lilly's pipeline, reducing early-stage risk compared to internal discovery.
AtaiBeckley's portfolio includes a secondary priority program, VLS-01, which is already progressing through an active Phase 2b clinical trial.
Risk Factors
The stock experienced a modest decline of 0.10% and settled near the day's lowest point following the announcement.
The contingent value rights structure includes no guarantee regarding the payment of any future consideration, making up to $1.0 billion dependent on uncertain outcomes.
The deal is projected to finalize in Q3 2026, requiring a long timeline for shareholder approval, regulatory clearances, and satisfaction of closing requirements.
Elevation Point Wealth Partners LLC significantly increased its stake in Eli Lilly and Company (NYSE: LLY) by 106.2% during the first quarter, purchasing an additional 21,749 shares to hold a total of 42,234 shares valued at approximately $38.8 million. This position represents 0.9% of Elevation Point's portfolio and ranks as its 16th largest holding. Several other institutional investors, including Sharp Wealth Advisory LLC, Platform Technology Partners, and Sound Income Strategies LLC, also increased their stakes in the pharmaceutical giant during the same period.
The article details specific financial metrics for Eli Lilly, noting a market capitalization of $1.14 trillion and a current share price opening at $1,208.37. Key valuation ratios include a price-to-earnings ratio of 42.93 and a PEG ratio of 1.51. The company maintains a debt-to-equity ratio of 1.26 and has recently declared a quarterly dividend of $1.73 per share, payable on September 10th to shareholders of record on August 14th.
Analyst sentiment remains mixed but generally positive, with major firms like Jefferies Financial Group and Goldman Sachs maintaining 'buy' ratings and target prices ranging from $1,283 to $1,350. However, HSBC recently downgraded the stock to a 'reduce' rating and lowered its price objective to $850. The consensus rating across MarketBeat is a 'Moderate Buy' with an average target price of $1,235.07, reflecting a diverse range of institutional opinions on the company's future performance.
π Elevation Point Wealth Partners increased Eli Lilly stake by 106.2% in Q1.
π° Position valued at $38.8M and represents 0.9% of total portfolio.
π HSBC downgraded stock to 'reduce' with new price target of $850.
πΌ Jefferies raised price target to $1,350 and maintained 'buy' rating.
ποΈ Institutional investors own 82.53% of outstanding Eli Lilly shares.
π Elevation Point Wealth Partners LLC increased its Eli Lilly stake by 106.2% in Q1, adding 21,749 shares to reach a total holding of 42,234 shares.
π° The institutional investor's position is valued at $38,846,000 and constitutes 0.9% of their total investment portfolio.
π Eli Lilly trades with a market cap of $1.14 trillion and a P/E ratio of 42.93 as of the latest filing data.
π΅ The company declared a quarterly dividend of $1.73 per share, resulting in an annualized yield of 0.6%.
π HSBC downgraded Eli Lilly from 'hold' to 'reduce' and cut its price target from $1,070 to $850.
πΌ Jefferies Financial Group raised its price target to $1,350 and reiterated a 'buy' rating on the stock.
π Goldman Sachs maintains a 'buy' rating with a specific price objective of $1,283.00 for the shares.
ποΈ Approximately 82.53% of Eli Lilly's outstanding shares are currently owned by hedge funds and institutional investors.
π The stock has a beta of 0.51, indicating lower volatility relative to the broader market.
π The ex-dividend date for the upcoming quarterly payout is set for Friday, August 14th.
Bullish Signals
Elevation Point Wealth increased position by 106.2% in Q1.
Multiple hedge funds and institutions also increased stakes.
Jefferies and Goldman Sachs maintain buy ratings above current price.
Healthy balance sheet with quick ratio of 1.10 and current ratio of 1.50.
Consistent dividend history with recent $1.73 quarterly payment.
Risk Factors
HSBC downgraded stock to reduce with $850 target.
P/E ratio of 42.93 indicates premium valuation.
Analysts show skepticism with one Sell and four Holds.
Bullish Signals
Elevation Point Wealth Partners LLC significantly increased its position by 106.2% in Q1, signaling strong institutional confidence.
Multiple other hedge funds and institutions, including Sharp Wealth Advisory and Platform Technology Partners, also increased their stakes.
Major brokerages like Jefferies Financial Group and Goldman Sachs maintain 'buy' ratings with target prices above the current trading level.
The company maintains a healthy balance sheet with a quick ratio of 1.10 and a current ratio of 1.50.
Eli Lilly has established a consistent dividend history, recently declaring a $1.73 quarterly payment.
Risk Factors
HSBC downgraded the stock to a 'reduce' rating and lowered its price objective significantly to $850.
The high P/E ratio of 42.93 suggests the stock is trading at a premium valuation compared to historical averages.
Analyst consensus includes one 'Sell' rating and four 'Hold' ratings, indicating some market skepticism.
Eli Lilly and Company (NYSE: LLY) shares have appreciated by approximately 6% over the last month, driven by strong market demand for its metabolic treatments, Mounjaro and Zepbound. Analysts from Leerink and Berenberg recently raised their price targets to $1,232 and $1,135 respectively, citing positive momentum in the company's core therapeutic areas.
On June 24, Eli Lilly completed its acquisition of Centessa Pharmaceuticals, a clinical-stage firm specializing in medicines for narcolepsy and sleep-wake disorders. The deal marks a strategic expansion into neuroscience, focusing on orexin receptor 2 agonists to target wakefulness and alertness. Following the announcement, LLY stock gained an additional 1.5%.
While the article highlights these positive developments and analyst upgrades, it concludes with a promotional pitch suggesting that certain AI stocks may offer superior short-term returns compared to LLY. The piece serves as a newsletter update rather than a deep-dive financial analysis of Lilly's long-term fundamentals.
π LLY shares rose 6% in past 30 days.
π― Leerink raised target to $1,232 on June 25.
π Strong demand continues for Mounjaro and Zepbound.
π€ Eli Lilly acquired Centessa Pharmaceuticals on June 24.
π§ Deal targets neuroscience with orexin receptor agonists.
π Eli Lilly (LLY) shares have risen roughly 6% over the past 30 days.
π― Leerink analyst David Risinger raised the price target to $1,232 with an Outperform rating on June 25.
π― Berenberg analyst Kerry Holford increased the price target to $1,135 while maintaining a Hold rating on June 22.
π Strong demand continues for metabolic treatments Mounjaro and Zepbound.
π€ Eli Lilly completed the acquisition of Centessa Pharmaceuticals on June 24.
π§ The acquired company focuses on orexin receptor 2 agonists for narcolepsy and sleep disorders.
π Stock price jumped approximately 1.5% immediately following the Centessa deal announcement.
π¬ The acquisition signals a strategic push into neuroscience and sleep medicine sectors.
Bullish Signals
Shares gained 6% over past month.
Analysts raised price targets at Leerink and Berenberg.
Strong demand for Mounjaro and Zepbound supports growth.
Eli Lilly and Company (LLY) concluded the first half of 2026 with a significant rally, pushing its stock price to a 52-week high of $1,207.59. The primary drivers for this performance were the demonstrated efficacy of retatrutide in treating severe obesity and robust sales figures for existing drugs Mounjaro and Kisunla.
Specifically, first-quarter revenue for Kisunla, the company's Alzheimer's medication, reached $124 million, representing a 490.5% year-over-year increase. Despite these strong operational metrics and LLY maintaining its status as a top performer in the $190 billion GLP-1 drugs market, an analyst from Allka Research has downgraded the stock rating to Hold.
The downgrade is attributed to two main factors: sluggish demand for the drug Omvoh and the stock trading at a non-GAAP forward P/E ratio of 31.1x, which the analyst deems less attractive given the current valuation. Technical analysis notes that after a minor pullback, the stock remains trading above the +2Ο band formed from the VWAP.
Consequently, while the pipeline and recent sales data remain exceptional, the combination of specific product headwinds and elevated valuation metrics has led to a more cautious outlook for investors looking at LLY as of June 26, 2026.
π Lilly stock hit $1,207.59 high by mid-2026.
π Kisunla sales surged 490.5% to $124 million.
π Rally driven by Mounjaro and retatrutide efficacy.
β οΈ Downgraded to Hold due to sluggish Omvoh demand.
π° Trades at 31.1x P/E, seen as unattractive entry.
π Eli Lilly stock reached a 52-week high of $1,207.59 by the end of the first half of 2026.
π First-quarter sales for Alzheimer's drug Kisunla hit $124 million, up 490.5% year-over-year.
π The rally is driven by strong performance in Mounjaro and the unprecedented efficacy of retatrutide for severe obesity.
β οΈ Analyst Allka Research downgraded LLY to a Hold rating due to sluggish demand for Omvoh.
π° The stock trades at a non-GAAP forward P/E ratio of 31.1x, cited as an unattractive entry point.
π Technical indicators show the stock trading above the +2Ο band formed from the VWAP after a small pullback.
π LLY is identified as a favorite within the $190 billion GLP-1 drugs market sector.
Bullish Signals
Stock hit new 52-week high of $1,207.59.
Kisunla sales grew 490.5% to $124 million.
Pipeline drug retatrutide shows unprecedented efficacy.
Mounjaro and Kisunla drive strong recent rally.
Company leads $190 billion GLP-1 drugs market.
Risk Factors
Sluggish Omvoh demand drags performance.
Non-GAAP forward P/E of 31.1x is unattractive.
Analyst downgraded to Hold due to valuation.
Bullish Signals
LLY stock reached a new 52-week high of $1,207.59, indicating strong recent momentum.
Kisunla generated $124 million in first-quarter sales, reflecting a massive 490.5% year-over-year growth.
The company's pipeline includes retatrutide, which is showing unprecedented efficacy in treating severe obesity.
Existing drugs Mounjaro and Kisunla are delivering strong performance that supports the recent rally.
LLY remains a top-ranked favorite within the massive $190 billion GLP-1 drugs market.
Risk Factors
Demand for the drug Omvoh is described as sluggish, acting as a drag on overall performance.
The stock trades at a non-GAAP forward P/E ratio of 31.1x, which an analyst considers an unattractive entry point.
An analyst has officially downgraded the rating from a previous bullish stance to Hold due to valuation concerns.
Eli Lilly has entered into a new collaboration agreement with Abbisko Therapeutics, a subsidiary of oncology specialist Abbisko Cayman, to jointly discover, develop, and potentially commercialize experimental medicines across multiple targets. The partnership focuses on early-stage drug programs aimed at accelerating the advancement of innovative therapeutic options for patients worldwide.
Under the terms of the deal, Abbisko Therapeutics will conduct discovery and early development activities while receiving an undisclosed upfront payment. Additionally, the company is eligible to receive up to approximately $1.9 billion in potential milestone payments tied to specific development, regulatory, and commercial achievements if those targets are met.
π€ Eli Lilly partners with Abbisko on experimental medicines.
π° Deal includes up to $1.9 billion in potential payments.
π Abbisko shares rose 4% after partnership announcement.
π¬ Agreement covers discovery and early development programs.
π Collaboration aims to bring new global treatment options.
π€ Eli Lilly collaborates with Abbisko Therapeutics on experimental medicines across multiple therapeutic targets.
π° Abbisko Therapeutics receives an undisclosed upfront payment plus potential milestone payments totaling up to $1.9 billion.
π Abbisko Cayman shares rose approximately 4% following the announcement of the partnership.
π¬ The agreement covers discovery and early development activities for new drug programs.
π Both companies aim to bring new treatment options to patients globally through this collaboration.
Bullish Signals
Abbisko secures up to $1.9 billion in milestone payments from Eli Lilly.
Eli Lilly partnership validates R&D capabilities and provides substantial capital resources.
Bullish Signals
Abbisko Therapeutics secures a significant potential deal value of up to $1.9 billion in milestone payments from Eli Lilly, indicating strong confidence in the pipeline's development and commercial potential.
The partnership with a major pharmaceutical giant like Eli Lilly validates Abbisko Therapeutics' R&D capabilities and provides substantial capital resources for advancing multiple drug programs.
Eli Lilly (LLY) and Pfizer (PFE) reported contrasting Q1 2026 results, with Lilly dominating the obesity market while Pfizer rebuilds post-pandemic. Lilly generated $19.80B in revenue, a 55.5% increase driven by Mounjaro ($8.66B) and Zepbound ($4.16B), achieving a 65% volume rise despite a 13% price decline to capture market share.
Pfizer reported $14.45B in revenue, up 5.4%, supported by Eliquis ($2.17B) and Padcev (up 39%), though it faced significant declines in COVID-related products like Comirnaty (-59%) and Paxlovid (-62%). The company recently acquired Metsera for approximately $7B to bolster its obesity pipeline, which now includes around 20 pivotal study starts.
Strategic differences define the two companies: Lilly secured FDA approval for Foundayo, the first oral GLP-1 pill without food or water restrictions, while Pfizer extended Vyndamax patent exclusivity to June 2031. Valuation metrics diverge sharply, with Lilly trading at a forward PE near 31 and analysts targeting $1,215.79, whereas Pfizer trades at a forward PE around 9 with a 6.61% dividend yield.
Eli Lilly (LLY) is facing intensified valuation scrutiny amidst social media discussions regarding its recent acquisition of 4E Therapeutics to expand chronic pain management. While observers note the strategic nature of this tuck-in deal, there are growing concerns about elevated stock multiples and potential red flags in rapid inventory growth and receivables that could pressure free cash flow conversion.
Despite these cautionary notes, bullish sentiment persists driven by reiterated outperform ratings and price targets near $1300. Analysts cite positive early data on acquired assets and long-term potential in metabolic therapies as key drivers. However, European regulatory developments are identified as a possible headwind to the company's international expansion plans.
Institutional activity reveals a mixed landscape with significant departures from major funds like J. Stern & Co., which removed nearly $3.7 billion in Q1 2026, offset by additions from firms like Fifth Third Bancorp and Assenagon Asset Management. Insider trading data shows heavy selling pressure from company executives, including the sale of over 298 million shares by Endowment Inc.
Financial performance highlights include Q1 2026 revenues of $19.8 billion, representing a 55.55% year-over-year increase. Wall Street consensus remains supportive with a median price target of $1280 and multiple analysts setting targets between $1183 and $1400, though the divergence in institutional holdings suggests ongoing debate over the stock's immediate trajectory.
π Q1 2026 revenue surged 55.55% to $19.8 billion.
π° Acquired 4E Therapeutics to expand chronic pain portfolio.
β οΈ Inventory and receivables growth raise cash flow concerns.
π Major institutions sold billions while others accumulated shares.
π― Analysts remain bullish with median price target of $1280.
π Eli Lilly reported Q1 2026 revenues of $19.8 billion, marking a significant 55.55% increase from the prior year.
π° The company recently acquired 4E Therapeutics to bolster its chronic pain management portfolio and complement existing oncology investments.
β οΈ Valuation concerns are rising due to rapid inventory growth and receivables that analysts fear could pressure free cash flow conversion.
π Insider selling is aggressive, with Endowment Inc. alone selling 298,610 shares for approximately $329 million in the last six months.
ποΈ Major institutional investors like J. Stern & Co. and Capital International Investors have significantly reduced their positions by billions of dollars in Q1 2026.
π Conversely, some funds are accumulating shares, with Fifth Third Bancorp adding over $1.3 billion and Assenagon Asset Management adding $1.1 billion.
π European regulatory developments are emerging as a potential headwind that could impact the company's international expansion plans.
π― Wall Street analysts maintain bullish ratings with a median price target of $1280, though individual targets range from $1183 to $1400.
π¬ Positive early data on acquired assets and long-term potential in metabolic therapies continue to fuel renewed bullish commentary.
π Guggenheim issued a 'Buy' rating with a price target of $1183, while Barclays set a higher target of $1400.
Bullish Signals
Q1 2026 revenues surged to $19.8 billion with 55.55% growth.
Analysts maintain outperform ratings with a median price target of $1280.
Acquisition expands pipeline in chronic pain management and oncology.
Positive early data on acquired assets drives renewed bullish commentary.
Institutional buying persists from Fifth Third Bancorp (+$1.36B) and Assenagon.
Risk Factors
Valuation concerns over optimistic assumptions.
Inventory growth pressures free cash flow.
Insiders sold 298,610 shares for $329M.
Institutions removed billions in Q1 2026.
European regulations hinder expansion.
Bullish Signals
Q1 2026 revenues surged to $19.8 billion, reflecting a robust 55.55% year-over-year growth rate.
Analysts maintain outperform ratings with a median price target of $1280 and individual targets reaching as high as $1400 from Barclays.
The acquisition of 4E Therapeutics strategically expands the pipeline in chronic pain management, complementing strong oncology investments.
Positive early data on acquired assets is driving renewed bullish commentary despite broader market caution.
Long-term potential in metabolic therapies remains a key growth driver supporting current valuations.
Institutional buying persists from specific funds like Fifth Third Bancorp (+$1.36B) and Assenagon Asset Management (+$1.10B), indicating selective confidence.
Risk Factors
Valuation scrutiny is intensifying with concerns that current multiples may already reflect overly optimistic assumptions.
Rapid inventory growth and increasing receivables are flagged as potential red flags that could pressure free cash flow conversion.
Significant insider selling occurred, with Endowment Inc. selling 298,610 shares for $329 million in the last six months.
Major institutional investors including J. Stern & Co. and Capital International Investors removed billions of dollars from their portfolios in Q1 2026.
European regulatory developments are identified as a possible headwind that could hinder international expansion plans.
Claris Financial LLC acquired a new stake in Eli Lilly and Company (LLY) valued at approximately $1.01 million during the fourth quarter, according to recent SEC filings. Several other institutional investors also adjusted their positions, with Brighton Jones LLC increasing holdings by 22.0% and Revolve Wealth Partners LLC adding 2.8% to its stake. Additionally, Schnieders Capital Management, Flow Traders U.S., and Nebula Research & Development established or increased their positions in the stock during the second quarter.
Analyst sentiment regarding LLY remains mixed with a consensus 'Moderate Buy' rating and an average target price of $1,227.74. Recent ratings include a downgrade from Weiss Ratings to a 'buy (b-)' and a reduction by HSBC from 'hold' to 'reduce,' which lowered their target price to $850. Conversely, Royal Bank Of Canada restated an 'outperform' rating, UBS Group maintained a 'buy' rating, and Leerink Partners set a target price of $1,119. The stock currently trades with a market cap of $1.03 trillion and a P/E ratio of 39.03.
Financially, Eli Lilly reported strong quarterly results ending April 30th, posting $8.55 EPS which significantly beat the consensus estimate of $6.97. Revenue reached $19.80 billion, surpassing estimates of $17.82 billion and representing a 55.5% year-over-year increase. The company has provided FY 2026 guidance ranging between $35.50 and $37.00 EPS, while analysts anticipate earnings of approximately $35.80 for the current year. A quarterly dividend of $1.73 was paid on June 10th to shareholders of record as of May 15th.
π Claris Financial acquired $1,007,000 LLY position in Q4.
π Brighton Jones increased stake to 9,597 shares worth $7.4M.
π HSBC cut target price from $1,070 to $850.
π° Q2 EPS of $8.55 beat estimates by $1.58.
π Revenue grew 55.5% to $19.80 billion in Q2.
π Claris Financial LLC acquired a new position in LLY valued at approximately $1,007,000 during the fourth quarter.
π Brighton Jones LLC increased its stake by 22.0%, now holding 9,597 shares worth $7,409,000.
π HSBC lowered its rating from 'hold' to 'reduce' and cut the target price from $1,070 to $850.
π Weiss Ratings downgraded LLY from a 'buy (b)' to a 'buy (b-)' rating in late May.
π° The company reported Q2 EPS of $8.55, beating analyst estimates of $6.97 by $1.58.
π Revenue for the quarter reached $19.80 billion, exceeding expectations of $17.82 billion.
π Quarterly revenue grew 55.5% compared to the same period in the previous year.
π― The company provided FY 2026 EPS guidance between $35.50 and $37.00.
π΅ A quarterly dividend of $1.73 was paid on June 10th with an annualized yield of 0.6%.
π The stock trades at a P/E ratio of 39.03 with a market capitalization of $1.03 trillion.
Bullish Signals
EPS beat expectations at $8.55 vs $6.97 estimate.
Revenue surged to $19.80 billion, beating estimates.
Quarterly revenue grew 55.5% year-over-year.
FY 2026 EPS guidance ranges from $35.50 to $37.00.
Stock rated Moderate Buy with $1,227.74 target price.
Risk Factors
HSBC downgraded stock to reduce with $850 target.
Weiss Ratings lowered rating from buy (b) to buy (b-).
Stock volatility ranges between $623.78 low and $1,182.73 high.
Bullish Signals
Eli Lilly significantly beat earnings expectations, reporting $8.55 EPS versus the consensus estimate of $6.97.
Revenue surged to $19.80 billion, surpassing analyst estimates of $17.82 billion by nearly $2 billion.
The company demonstrated robust growth with quarterly revenue increasing 55.5% year-over-year.
Management provided strong forward guidance for FY 2026, projecting EPS between $35.50 and $37.00.
Analysts anticipate the company will post approximately $35.80 EPS for the current year, aligning with or exceeding guidance.
The stock maintains a 'Moderate Buy' consensus rating from MarketBeat with an average target price of $1,227.74.
Risk Factors
HSBC downgraded the stock from 'hold' to 'reduce' and lowered its target price significantly to $850.
Weiss Ratings recently downgraded the stock from a 'buy (b)' to a slightly lower 'buy (b-)' rating.
The stock has experienced volatility, trading between a twelve-month low of $623.78 and a high of $1,182.73.
On June 9, the US FDA approved a new eight-week maintenance dosing regimen for Eli Lilly's (LLY) EBGLYSS (lebrikizumab-lbkz). This approval allows adults and children aged 12 and older with moderate-to-severe atopic dermatitis to receive a single injection once every eight weeks, reducing the frequency from the previous schedule.
EBGLYSS becomes the only treatment option capable of managing the condition with as few as six maintenance injections per year without requiring concomitant prescription topicals. The dosing update is based on longitudinal exposure-response modeling and data from the Phase 3 ADjoin long-term extension trial, which involved a 32-week study period.
Clinical data from the extension study demonstrated durable disease control with no new safety signals or patient discontinuations due to adverse events. Management highlighted that this regimen provides significant flexibility for patients aiming to reduce the burden of daily symptom management and frequent injections. The most commonly reported side effects remain consistent with the existing profile, including conjunctivitis, injection site reactions, and herpes zoster.
This regulatory milestone reinforces EBGLYSS's position in the atopic dermatitis market by offering a convenient long-term maintenance option that eliminates the need for daily topical therapies. The approval expands the drug's utility and convenience factor, potentially influencing prescribing patterns and patient adherence in the competitive landscape of skin disease treatments.
π FDA approved 8-week maintenance dosing for EBGLYSS on June 9.
π₯ Regimen covers adults and children 12+ with moderate-to-severe atopic dermatitis.
π Single injection every 8 weeks replaces more frequent dosing schedules.
π Only treatment manageable with as few as six injections per year.
π« Maintenance no longer requires concomitant prescription topical medications.
π FDA approved an eight-week maintenance dosing regimen for Eli Lilly's EBGLYSS on June 9.
π₯ The new regimen applies to adults and children aged 12 and older with moderate-to-severe atopic dermatitis.
π Patients can now receive a single injection once every 8 weeks instead of more frequent dosing.
π EBGLYSS becomes the only treatment option manageable with as few as six maintenance injections per year.
π« The new regimen does not require concomitant prescription topicals for maintenance.
π Approval is based on data from the Phase 3 ADjoin long-term extension trial covering 32 weeks.
β Clinical data showed durable disease control without new safety signals or discontinuations due to adverse events.
π‘οΈ Common side effects remain consistent with the existing profile including conjunctivitis and injection site reactions.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)